Ralinepag works by restoring prostacyclin signaling and activating prostacyclin receptors to affect pathways that play a role in the progression of PAH. The drug was originally formulated as an ...

Ralinepag, a prostacyclin receptor agonist, added to background therapy decreased the risk for a clinical worsening event in ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., May 17, 2026--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that full results of its ADVANCE OUTCOMES ...

United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically ...

Panelists discuss how sotatercept represents a paradigm shift as the first activin signaling inhibitor showing dramatic improvements in heavily pretreated patients, with the Stellar and Zenith trials ...

Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight The pulmonary arterial hypertension clinical trial ...

This article and associated images are based on a poster originally authored by Ravinder K. Bhardwaj, Eline Koers, Alexander Krull, David Sykes, Dmitry Veprintsev and Neil V. Morgan and presented at ...

In a new report, the Midwest Institute for Clinical and Economic Review's (ICER) Comparative Effectiveness Public Advisory Council concluded that the Merck drug sotatercept, currently under review by ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Findings in The American Journal of Pathology open avenues for development of therapeutic strategies to enhance membrane repair and prevent preterm birth “Preterm birth is a major challenge in ...